“Neural Lace Breakthrough: First Human Trials Enable ‘Thought-to-Text’ at 90% Accuracy”
SAN FRANCISCO — Synchron Inc. announced FDA approval for its Stentrode² neural interface on Tuesday, enabling paralyzed patients to control digital devices via brain signals. Unlike bulky predecessors, this coin-sized implant converts neural activity into text with unprecedented precision, utilizing quantum machine learning algorithms developed in partnership with CERN…
Piece includes ethical debates from MIT Technology Review, demonstrations at CES 2025, and implications for the $320B neurotech market.